Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Deborah Rotenstein

Pediatric Endocrinology Pittsburgh, PA Medical Doctor

NPI 1588669030 CMS profile 207400

1350 Locust St, Ste 306, Pittsburgh, PA 15219

Open in the dashboard

General payments

$72,911

95 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Deborah Rotenstein of Pittsburgh, PA is reported in the CMS Open Payments database as having received $72,911 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $22 1
2022 General $885 2
2021 General $28,132 21
2020 General $6,488 12
2019 General $37,383 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deborah Rotenstein
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Deborah Rotenstein were reported at $0. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Deborah Rotenstein Pediatric Endocrinology median Middle half National median
2019 $37,383 $196 $68–$845 $163
2020 $6,488 $124 $37–$722 $114
2021 $28,132 $134 $35–$691 $132
2022 $885 $177 $47–$726 $149
2023 $22 $236 $75–$887 $160
2024 $0 $259 $91–$979 $164
2025 $0 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Ultragenyx Pharmaceutical Inc. $22,554 33 payments
  2. TOLMAR Pharmaceuticals, Inc. $22,140 3 payments
  3. Ipsen Biopharmaceuticals, Inc $17,432 5 payments
  4. AbbVie, Inc. $3,925 14 payments
  5. Novo Nordisk Inc $3,502 22 payments
  6. Ferring Pharmaceuticals Inc. $3,201 9 payments
  7. BioMarin Pharmaceutical Inc. $65 3 payments
  8. Lilly USA, LLC $47 3 payments
  9. Pfizer Inc. $31 2 payments
  10. Arbor Pharmaceuticals, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Consulting Fee $24,735 6 payments
  2. Honoraria $23,005 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,444 14 payments
  4. Travel and Lodging $3,718 10 payments
  5. Food and Beverage $2,010 61 payments
Products named General payments · program years 2019–2023
  1. FENSOLVI $22,140 3 payments
  2. INCRELEX $17,432 5 payments
  3. Crysvita Xlh $10,373 17 payments
  4. Cryvista $4,775 5 payments
  5. Crysvita XLH Metabolic Bone Disorder $4,582 8 payments
  6. LUPRON DEPOT $3,820 8 payments
  7. ZOMACTON $3,201 9 payments
  8. Norditropin Growth Hormone $2,954 14 payments
  9. Norditropin Growth Hormone $434 2 payments
  10. Norditropin Growth Hormone $114 6 payments
  11. Other $289 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record